TIDMNPH
RNS Number : 2706Y
Neuropharm Group PLC
01 September 2009
?
+------------------------------------------+------------------------------------+
| For immediate release | 1 September 2009 |
+------------------------------------------+------------------------------------+
Neuropharm Group plc
("Neuropharm" or "the Company")
Notice of Preliminary Results
Neuropharm Group plc (AIM: NPH), a specialty pharmaceutical company focused on
neurodevelopmental disorders, will announce its preliminary results for the year
ended 30 June 2009 on Wednesday 30 September 2009.
For further information please contact:
+-----------------------------------------------+--------------------+
| Neuropharm | + 44 (0) 1372 371 |
| | 171 |
+-----------------------------------------------+--------------------+
| Robert Mansfield, Chief Executive Officer | |
| Graham Yeatman, Chief Financial Officer | |
+-----------------------------------------------+--------------------+
| | |
+-----------------------------------------------+--------------------+
| Piper Jaffray Ltd. | + 44 (0) 20 3142 |
| | 8700 |
+-----------------------------------------------+--------------------+
| Neil Mackison, Rupert Winckler | |
+-----------------------------------------------+--------------------+
| | |
+-----------------------------------------------+--------------------+
| Buchanan Communications | + 44 (0) 20 7466 |
| | 5000 |
+-----------------------------------------------+--------------------+
| Mark Court, Mary-Jane Elliot, Catherine Breen | |
+-----------------------------------------------+--------------------+
Notes to Editors:
About Neuropharm
Neuropharm is a speciality pharmaceutical company focused on the development of
medicines for the treatment and management of neurodevelopmental disorders.
Please visit www.neuropharm.co.uk for further information.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORFGGFRMMLGLZZ
|